3172 results for «358»
3172 results
Protect the brain for TAVI - True potential of SENTINEL Cerebral Protection System
14 Feb 2026 – From PCR Tokyo Valves 2026
This session highlights the critical role of cerebral protection during TAVI procedures by focusing on the SENTINEL Cerebral Protection System. It reviews trends in the United States and Japan, presents clinical outcomes one year post-introduction in Japan, and examines key clinical trials through a meta-analysis comparing...
Mastering techniques from basic to complex - Tips and tricks for advanced mitral TEER: anatomy and imaging
13 Feb 2026 – From PCR Tokyo Valves 2026
Advance your expertise in mitral TEER by gaining anatomical insights, understanding device interaction with native valve structures, and learning to prevent and manage procedural complications through case-based imaging and live assessments.
Mastering techniques from basic to complex - Tricuspid TEER fundamentals
13 Feb 2026 – From PCR Tokyo Valves 2026
Gain foundational knowledge in tricuspid TEER by understanding anatomical criteria for patient suitability, key procedural steps, and device techniques, enhanced by simulation-based procedural training.
Getting ready for tricuspid TEER: key steps in building a successful programme
14 Feb 2026 – From PCR Tokyo Valves 2026
Prepare to establish a successful tricuspid TEER programme by understanding essential components such as systematic echocardiographic and clinical assessments for patient selection, procedural fundamentals, and programme development supported by clinical evidence.
Patient selection for tricuspid TEER in 2026
14 Feb 2026 – From PCR Tokyo Valves 2026
This session focuses on optimizing patient selection for tricuspid transcatheter edge-to-edge repair (TEER) in 2026. It integrates anatomical, haemodynamic, and clinical criteria to identify ideal candidates, explores evolving treatment boundaries between TEER, transcatheter tricuspid valve replacement (TTVR), and medical management, and applies evidence from key trials...
Procedural optimisation for enhanced acute and long-term outcomes
14 Feb 2026 – From PCR Tokyo Valves 2026
This session emphasizes procedural optimization in TAVI to enhance both acute and long-term outcomes. It highlights critical factors such as valve sizing, expansion, implantation depth, and commissural alignment. Practical techniques for pre- and post-dilatation alongside commissural alignment are demonstrated through real cath lab cases, underscoring their...
Team approach to structural heart disease: how to handle unexpected situations
14 Feb 2026 – From PCR Tokyo Valves 2026
This session highlights the multidisciplinary team approach to managing structural heart disease, focusing on responses to unexpected intraoperative and postoperative situations. It features real-world experiences from a TAVI radiologic technologist, clinical engineer, TEER sonographer, and TEER nurse, emphasizing their respective roles in addressing intraoperative events, sudden...
SURTAVI: five-year results from a randomized trial of TAVR vs. SAVR in patients at intermediate surgical risk
07 Nov 2021
Although TAVI is an accepted alternative to surgery in patients with severe aortic stenosis who are at high surgical risk, less is known about long-term comparative outcomes among patients with aortic stenosis who are at intermediate surgical risk. P. Redaelli & M. Pighi review the SURTAVI trial...
Author
Author
World Heart Day 2023: Reducing the burden of cardiovascular disease globally: beyond stents and balloons!
29 Sep 2023
Global burden of Cardiovascular Disease
Cardiovascular disease (CVD) remains the lead cause of mortality for men and women globally. Our world population in 2023 is 8 billion! Of these, around 620 million people are living with heart and circulatory diseases across the world. Each year around 60...
Author
BRIGHT-4 – Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial
07 Nov 2022
Nicola Ryan provides her take on the BRIGHT-4 study, which was presented during AHA 2022 in Chicago, & simultaneously published in the Lancet.
This study was a randomised control trial designed to assess if bivalirudin plus a high dose infusion for 2-4 hours post PPCI was superior to unfractionated...
Author
The Lancet Commission to reduce global burden of cardiovascular disease in women by 2030
29 Aug 2021
Vijay Kunadian summarizes the key points of the LBT session of the ESC congress 2021 held on Sunday, 29 August focusing on the Lancet Commission to reduce the global burden of heart disease in women by 2030.
Author
Drug-coated balloon (DCB) technology: A pioneer’s view of the historical evolution and future directions
08 Jan 2025
In this article, Bruno Scheller explores advances in local drug delivery, from drug-coated balloons to novel antiproliferative agents. These innovations aim to reduce restenosis, minimize permanent implants, and pave the way for patient-specific coronary artery disease treatments.
Author
